All Insights

Illumina lost 27% of its China revenue in one quarter after being blacklisted — retaliation for lobbying against its own top competitor, BGI. The company's CEO was the only life sciences executive in Trump's May 2026 Beijing delegation, while Pfizer and Eli Lilly stayed away, already deep in $50 billion of licensing deals that needed no summit at all.

China's alternative to SWIFT processed $24.5 trillion in 2024, projected to hit $30 trillion in 2025 — and the renminbi's share of global trade finance has quadrupled. The infrastructure for a serious dollar alternative isn't hypothetical anymore; it's already running.

Washington quietly cleared Nvidia's H200 AI chips for sale to Alibaba, Tencent, and ByteDance — announced through regulatory action, not summit fanfare. Six tech CEOs came to Beijing not chasing new opportunity, but defending dependencies years and billions in the making.

China hit its 2030 wind and solar target six years early, then set a new goal of 3,600 gigawatts by 2035 — more than doubling again. Three blocs, three completely different playbooks (state-directed speed, binding EU law, US private capital), all converging on the same 47-52% wind and solar destination by 2055.

Most AI inference runs through three cloud providers and one or two chip manufacturers — a single point of failure smaller than a mid-sized corporate IT department, for the entire global AI stack. Why AI dominance is no longer the real question, and what building resilience around it actually requires.

A hospital running AI-assisted radiology for a decade doesn't have the radiologists to revert — they were never hired, never trained. Why the fallback to pre-AI operation isn't a step backward in time for the most dependent industries. It's a step off a cliff.

AI has quietly become the third layer of critical infrastructure, after power and internet — but unlike those systems, it has no equivalent resilience standards, regulatory oversight, or stress-testing. A sector-by-sector risk map of what breaks first, and why the fallback keeps disappearing.

SMMT's 5-year bull case reaches 500-1000% — but carries a real scenario of losing nearly everything. LLY, despite an 800% run since 2019, now trades at 38x earnings with a base case barely ahead of the S&P 500. A side-by-side scenario analysis across three completely different risk profiles.

A tech company's marginal cost of serving one more customer is fractions of a penny. A pharma company's cost scales with every pill manufactured, shipped, and monitored. That single structural difference explains more of the tech-pharma performance gap than any other factor — and it's not the whole story.

Institutional-quality pharma research requires no Bloomberg terminal — it requires knowing that FDA Medical Reviews, R&D Day slide decks, and ClinicalTrials.gov protocols exist, and reading them critically. A complete map of every public source serious pharma investors use, and a step-by-step research workflow you can apply to any company.